27.11.2014 Views

A Guide to Primary Care of People with HIV/AIDS - Canadian Public ...

A Guide to Primary Care of People with HIV/AIDS - Canadian Public ...

A Guide to Primary Care of People with HIV/AIDS - Canadian Public ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

11<br />

86<br />

A <strong>Guide</strong> <strong>to</strong> <strong>Primary</strong> <strong>Care</strong> <strong>of</strong> <strong>People</strong> <strong>with</strong> <strong>HIV</strong>/<strong>AIDS</strong><br />

Chapter 11: Postexposure Prophylaxis<br />

INTERVENTIONS FOR PEP<br />

IN HEALTH CARE SETTINGS<br />

What types <strong>of</strong> exposures merit consideration<br />

<strong>of</strong> PEP in health care personnel (HCP)?<br />

HCP are at increased risk from percutaneous, mucous<br />

membrane, and nonintact skin exposures <strong>to</strong> bloodborne<br />

pathogens, including hepatitis B, hepatitis C, and <strong>HIV</strong>.<br />

The risk <strong>of</strong> transmission is dependent on many fac<strong>to</strong>rs,<br />

including the type, amount, route, and severity <strong>of</strong><br />

exposure, the infection status <strong>of</strong> the source, and the HBV,<br />

HCV, and <strong>HIV</strong> immunity <strong>of</strong> the exposed worker (see<br />

Tables 11-1 and 11-2).<br />

Table 11-1. High-risk<br />

Occupational Exposures<br />

Exposures <strong>with</strong> higher risk <strong>of</strong><br />

transmission <strong>of</strong> bloodborne pathogens<br />

Deep percutaneous injury<br />

Injury <strong>with</strong> a hollow-bore blood-filled needle<br />

Exposure <strong>to</strong> blood <strong>of</strong> a patient in an advanced disease stage<br />

(high viral load)<br />

Exposure <strong>to</strong> a large quantity <strong>of</strong> blood or body fluids<br />

Table 11-2. Exposures <strong>with</strong> Low Risk <strong>of</strong><br />

Transmission <strong>of</strong> Bloodborne Pathogens<br />

Exposures <strong>with</strong> low risk <strong>of</strong><br />

transmission (PEP not recommended)<br />

Blood or fluid splashes on intact skin<br />

Minor scratches or abrasions <strong>with</strong>out evidence <strong>of</strong> percutaneous<br />

penetration<br />

Penetration by small-bore needles <strong>with</strong>out visible blood<br />

An accurate his<strong>to</strong>ry <strong>of</strong> the exposure is essential in<br />

determining the real risk <strong>of</strong> transmission. In studies,<br />

transmission <strong>of</strong> <strong>HIV</strong> by occupational exposure has an<br />

estimated 0.3% risk <strong>with</strong> percutaneous exposure and<br />

0.09% <strong>with</strong> mucous membrane splash (Bell, 1997).<br />

The risk <strong>of</strong> infection for HBV (in individuals who have<br />

not been vaccinated <strong>to</strong> hepatitis B, or who were vaccine<br />

unresponsive) after percutaneous exposure is 37%-62%<br />

when the source is hepatitis B surface antigen (HbsAg)<br />

positive and hepatitis B e antigen (HBeAg) positive, and<br />

the risk <strong>of</strong> developing clinical hepatitis is 22%-31%.<br />

When the source is HbsAg positive and hepatitis B e<br />

antigen negative, the risk <strong>of</strong> HBV seroconversion is<br />

1%-6%, and the risk <strong>of</strong> developing clinical hepatitis is<br />

23%-37%. The risk <strong>of</strong> transmission is higher, ie 22%-<br />

31%, when the source has clinically evident hepatitis<br />

B hepatitis (Werner and Grady, 1982; CDC, 2001).<br />

Transmission <strong>of</strong> HCV through occupational exposure<br />

carries an average risk <strong>of</strong> 1.8%.<br />

What are immediate actions and initial<br />

considerations in PEP following a possible<br />

occupational exposure?<br />

First aid for the HCP is the first immediate action,<br />

followed by collection <strong>of</strong> information in order <strong>to</strong> assess<br />

the situation and make rapid decisions regarding<br />

appropriate treatment (see Tables 11-3, 11-4, and 11-5).<br />

Quick, expert action by the care provider is essential<br />

because the effectiveness <strong>of</strong> PEP is variable and<br />

depends on the inoculum, type <strong>of</strong> injury, potency <strong>of</strong><br />

the PEP regimen, and speed <strong>with</strong> which treatment is<br />

started. The decision <strong>to</strong> prescribe medications, as well<br />

as medication administration, should be made <strong>with</strong>in<br />

4 hours <strong>of</strong> the exposure, and must be made <strong>with</strong>in<br />

72 hours, and preferably sooner because <strong>of</strong> studies<br />

suggesting that the efficacy <strong>of</strong> PEP is diminished after<br />

36 hours. Even <strong>with</strong> optimal implementation, ie <strong>with</strong>in<br />

the first 4 hours, the protection afforded by PEP is not<br />

100%.<br />

What counseling and education should you<br />

give the HCP?<br />

The exposed HCP needs immediate counseling <strong>to</strong><br />

assist in coping <strong>with</strong> the emotional stress <strong>of</strong> the<br />

exposure, and may require follow up care by a mental<br />

health pr<strong>of</strong>essional. Psychological services should be<br />

available 24 hours a day, 7 days a week. A local crisis<br />

management team or an employee assistance program<br />

(EAP) may be effective ways <strong>to</strong> address this need.<br />

The HCP should be <strong>to</strong>ld the relative risk <strong>of</strong> infection<br />

<strong>with</strong> <strong>HIV</strong>, HBV, and HCV following exposure, the<br />

effectiveness <strong>of</strong> PEP, and the risks and benefits <strong>of</strong><br />

PEP. Exposed persons should be advised <strong>to</strong> return<br />

immediately if symp<strong>to</strong>ms <strong>of</strong> acute <strong>HIV</strong> seroconversion<br />

occur, including fever, malaise, rash, swollen lymph<br />

nodes, fatigue or myalgias (most likely <strong>to</strong> occur 2-6<br />

weeks after exposure).<br />

Providers should advise exposed HCPs <strong>to</strong> prevent<br />

transmitting <strong>HIV</strong> <strong>to</strong> others, by means <strong>of</strong> the following<br />

measures, until the HCP has a negative <strong>HIV</strong> test 6<br />

months after exposure:<br />

• Refrain from donating blood, plasma, organs, tissue,<br />

or semen.<br />

• Use barrier protection during sexual activity.<br />

• If HCP is female, avoid pregnancy.<br />

• If breast feeding, consider discontinuing, <strong>to</strong> avoid the<br />

risk <strong>of</strong> <strong>HIV</strong> transmission through breast milk.<br />

If exposed <strong>to</strong> HBV, the HCP should follow infection<br />

control procedures that are in place at the institution.<br />

U.S. Department <strong>of</strong> Health and Human Services, Health Resources and Services Administration, <strong>HIV</strong>/<strong>AIDS</strong> Bureau

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!